Arbutus Biopharma Corp (NASDAQ:ABUS) — Market Cap & Net Worth
Market Cap & Net Worth: Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ:ABUS) has a market capitalization of $840.56 Million ($840.56 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9912 globally and #2545 in its home market, demonstrating a 1.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arbutus Biopharma Corp's stock price $4.32 by its total outstanding shares 195478068 (195.48 Million). Analyse ABUS cash flow conversion to see how efficiently the company converts income to cash.
Arbutus Biopharma Corp Market Cap History: 2015 to 2026
Arbutus Biopharma Corp's market capitalization history from 2015 to 2026. Data shows change from $869.88 Million to $844.47 Million (-3.69% CAGR).
Index Memberships
Arbutus Biopharma Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #268 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #994 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.05% | #158 of 263 |
Weight: Arbutus Biopharma Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arbutus Biopharma Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arbutus Biopharma Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
66.76x
Arbutus Biopharma Corp's market cap is 66.76 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $478.92 Million | $1.50 Million | -$384.10 Million | 319.28x | N/A |
| 2017 | $987.16 Million | $10.70 Million | -$84.40 Million | 92.26x | N/A |
| 2018 | $748.68 Million | $5.90 Million | -$57.10 Million | 126.90x | N/A |
| 2019 | $543.43 Million | $6.01 Million | -$153.72 Million | 90.41x | N/A |
| 2020 | $693.95 Million | $6.91 Million | -$63.74 Million | 100.37x | N/A |
| 2021 | $760.41 Million | $10.99 Million | -$76.25 Million | 69.20x | N/A |
| 2022 | $455.46 Million | $39.02 Million | -$69.46 Million | 11.67x | N/A |
| 2023 | $488.70 Million | $18.14 Million | -$72.85 Million | 26.94x | N/A |
| 2024 | $639.21 Million | $6.17 Million | -$69.92 Million | 103.58x | N/A |
| 2025 | $940.25 Million | $14.08 Million | -$33.50 Million | 66.76x | N/A |
Competitor Companies of ABUS by Market Capitalization
Companies near Arbutus Biopharma Corp in the global market cap rankings as of May 2, 2026.
Key companies related to Arbutus Biopharma Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Arbutus Biopharma Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Arbutus Biopharma Corp's market cap moved from $869.88 Million to $ 844.47 Million, with a yearly change of -3.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $844.47 Million | -10.19% |
| 2025 | $940.25 Million | +47.09% |
| 2024 | $639.21 Million | +30.80% |
| 2023 | $488.70 Million | +7.30% |
| 2022 | $455.46 Million | -40.10% |
| 2021 | $760.41 Million | +9.58% |
| 2020 | $693.95 Million | +27.70% |
| 2019 | $543.43 Million | -27.42% |
| 2018 | $748.68 Million | -24.16% |
| 2017 | $987.16 Million | +106.12% |
| 2016 | $478.92 Million | -44.94% |
| 2015 | $869.88 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Arbutus Biopharma Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $840.56 Million USD |
| MoneyControl | $840.56 Million USD |
| MarketWatch | $840.56 Million USD |
| marketcap.company | $840.56 Million USD |
| Reuters | $840.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more